Anew study analyzed 945 patients with prostate cancer managed on active surveillance. Researchers found that men with intermediate-risk cancer had a 3.75 higher chance of dying from prostate cancer than men with low-risk disease within 15 years (11.5% vs. 3.7%). The authors said this is the first study to examine long-term outcomes of patients with low- vs. intermediate-risk prostate cancer managed on active surveillance.
The 10-year overall survival rates for men with intermediate-risk prostate cancer were 68.4%, compared to 83.6% for men with low-risk disease. The 15- year overall survival rates for men with intermediate-risk prostate cancer were 50.3%, compared to 68.8% for low-risk patients. The lower survival rates for men with intermediate-risk disease suggested these patients had lower life expectancy.
Men with intermediate-risk cancer had a PSA >10 ng/ml, Gleason score 7 or clinical stage T2b/2c.
The men in the study were on active surveillance between 1995 and 2013 at the Sunnybrook Health Sciences Centre in Canada. Of the subjects, 237 men had intermediate-risk prostate cancer and 708 men had low-risk cancer. Patients whose cancer worsened were offered treatment (radiation or surgery). Eighty-six patients (36.5%) in the intermediate-risk group received treatment.
The findings were presented at the 2015 Genitourinary Cancers Symposium in Orlando, Florida.